Table 4.

ELISA evaluation of plasma interleukin 6 (IL‐6) and tumour necrosis factor alpha (TNF‐α) levels during the study in enrolled patients with DVT (Group A), with DVT + PTS (Group B) and in control group (Group C) at the time of admission (T0) and 1 (T1), 4 (T2), 8 (T3), 12 (T4) and 18 (T5) months later

	T0	T1	T2	T3	T4	T5
Group A
IL‐6	9·1 ± 3·2**	8·7 ± 2·4**	8·5 ± 2·9**	7·5 ± 4·2*	5·4 ± 3·5*	4·6 ± 3·7
TNF‐α	7·8 ± 3·2**	7·4 ± 2·8**	6·8 ± 2·2**	5·9 ± 3·1*	4·2 ± 1·9	3·9 ± 1·8
Group B
IL‐6	9·4 ± 3·5**	8·8 ± 3·1**	7·5 ± 3·6**	7·2 ± 2·1*	5·7 ± 2·3*	3·8 ± 2·4
TNF‐α	7·6 ± 3·5**	7·5 ± 2·9*	6·7 ± 2·1**	5·7 ± 2·2*	3·9 ± 2·8	3·8 ± 2·5
Group C
IL‐6	3·9 ± 2·1	3·7 ± 1·9	3·7 ± 2·0	3·8 ± 2·1	3·7 ± 2·3	3·8 ± 2·4
TNF‐α	3·8 ± 2·5	3·6 ± 2·2	3·9 ± 2·7	3·5 ± 2·3	3·7 ± 2·4	3·7 ± 2·3

Values are expressed in pg/mL as mean ± SEM.

DVT, deep vein thrombosis; ELISA, enzyme‐linked immunosorbent assay; PTS, post‐thrombotic syndrome.

^* P < 0·05 and

^** P < 0·01 versus Group C.